( Three Oritavancin Studies Presented at ...)Targanta Reports Improved Ability of Oritavancin to Stop Bacteria,Growth In Vitro Compared With Other Glycopeptide Antibiotics,Health

MUNICH, Germany, April 03, 2007 /PRNewswire/ -- Targanta Therapeutics today announced results from two studies showing the improved potency of oritavancin to stop bacterial growth in vitro when tested with a common wetting agent (polysorbate 80) and one study demonstrating the activity of oritavancin against S. pneumoniae in a mouse model of pneumonia. Oritavancin, a novel lipoglycopeptide antibiotic, is Targanta's lead product currently in post- Phase 3 clinical development. These findings were presented at the 17th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) and 25th International Congress of Chemotherapy (ICC) in Munich, Germany from March 31 - April 3, 2007.

"We are encouraged by the research demonstrating the improved activity of oritavancin when compared with other glycopeptide antibiotics. By combining oritavancin with a common wetting agent, it is evident that the ability of the treatment to inhibit bacteria growth, demonstrated through previous research, may be underestimated based on these recent studies," said Thomas Parr, Ph.D., Chief Scientific Officer, Targanta Therapeutics. "These data further support oritavancin as a potential treatment for serious bacterial infections, and Targanta will continue to explore this potential through ongoing clinical research."

    The following research was presented at the ECCMID/ICC meeting:

      --  Effect of polysorbate 80 on oritavancin binding to plastic surfaces

          -- implications for susceptibility testing (ECCMID/ICC07-P 1112)

      --  Influence of polysorbate 80 on susceptibility of gram-positive

          bacteria to oritavancin (ECCMID/ICC07-P 827)

      --  Efficacy of oritavancin in a mouse model of Streptococcus pneumoniae

          pneumonia (ECCMID/ICC07-P 1781)


    Study Methods and Results:

    --  Effect of polysorbate 80 on oritavancin binding to plastic surfaces --

        implic
'"/>




Page: 1 2 3 4 5 6 
Related medicine technology :

1. Targanta Study Shows Oritavancin Treatment Effective in a Mouse
Model of Anthrax
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology
With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal
Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III
Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with
CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for
Revlimid Presented at the International Myeloma Workshop in Greece
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018
Injection
9. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
10. Columbia Laboratories Reports Positive Results from Multi-dose
Pharmacokinetic Study of Vaginally-administered Lidocaine
11. CytRx Reports Promising Data from Its Open-Label Extension Clinical
Trial of Arimoclomol in ALS